The distribution of non-Hodgkin lymphoma (NHL) subtypes differs around the world but a systematic study of Latin America has not been done. Therefore, we evaluated the relative frequencies of NHL subtypes in Central and South America (CSA). Five expert hematopathologists classified consecutive cases of NHL from 5 CSA countries using the WHO classification and compared them to 400 cases from North America (NA). Among the 1028 CSA cases, the proportions of B- and T-cell NHL and the sex distribution were similar to NA. However, the median age of B-cell NHL in CSA (59 years) was significantly lower than in NA (66 years; P < .0001). The distribution of high-grade (52.9%) and low-grade (47.1%) mature B-cell NHL in CSA was also significantly different from NA (37.5% and 62.5%; P < .0001). Diffuse large B-cell lymphoma was more common in CSA (40%) than in NA (29.2%; P < .0001), whereas the frequency of follicular lymphoma was similar in Argentina (34.1%) and NA (33.8%), and higher than the rest of CSA (17%; P < .001). Extranodal NK/T-cell NHL was also more common in CSA (P < .0001). Our study provides new objective evidence that the distribution of NHL subtypes varies significantly by geographic region and should prompt epidemiologic studies to explain these differences.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1182/blood-2012-07-440073 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Primary head and neck lymphoid neoplasms in adolescents and young adults: demographics, distribution and survival outcomes.
Ann Hematol
December 2024
Medical Center of Hematology, Xinqiao Hospital, Army Medical University, No.83 Xinqiao Road, Chongqing, 400037, China.
Primary head and neck lymphoid neoplasms(PHNLN) are described as a series of lymphoid system-derived neoplasms which originally arising from head and neck region. Our study is aimed to present a panoramic view of PHNLN among adolescent and young adult(AYA) patients aged from 15 to 39 years-old. The individual patient information was obtained from Surveillance, Epidemiology and End Results(SEER) database.
View Article and Find Full Text PDFTemporal changes in the burden of leukaemia and lymphoma in the Australasia and Oceania regions, 2010-2019: an analysis of the Global Burden of Disease Study 2019.
BMJ Open
November 2024
Deakin Health Economics, Deakin University School of Health and Social Development, Burwood, Victoria, Australia.
Article Synopsis
- This study investigates the prevalence and trends of leukaemias and lymphomas in Australasia and Oceania from 2010 to 2019, focusing on key subtypes like AML and NHL.
- Using data from the Global Burden of Disease 2019, the research analyzes incidence, prevalence, disability-adjusted life years (DALYs), and deaths across different age groups and sexes.
- Findings indicate that AML and NHL are the leading cancers in both regions, with Australasia showing overall increases in disease burden during the study period, while Oceania has mixed trends in mortality and prevalence across various leukaemias and lymphomas.
Evaluating plasma antinuclear autoantibody profile as a prognostic biomarker in lymphoma.
BMC Cancer
November 2024
Clinical Pharmacology Research Center, Peking Union Medical College Hospital, State Key Laboratory of Complex Severe and Rare Diseases, NMPA Key Laboratory for Clinical Research and Evaluation of Drug, Beijing Key Laboratory of Clinical PK and PD Investigation for Innovative Drugs, Chinese Academy of Medical Sciences and Peking Union Medical College, No.1 Shuaifuyuan, Dongcheng District, Beijing, 100730, China.
Background: Research on the antinuclear antibodies (ANA) profile across different pathological subtypes of lymphoma was limited. Our study aimed to assess ANA profile and investigate its potential prognostic value in lymphoma.
Method: We collected plasma samples from 139 lymphoma patients and analyzed the expression of plasma ANA, SSA, and SSB using the enzyme-linked immunosorbent assay (ELISA).
Bromodomain proteins as potential therapeutic targets for B-cell non-Hodgkin lymphoma.
Cell Biosci
November 2024
The Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing, China.
Background: B-cell non-Hodgkin lymphoma (B-NHL) is the most common type of lymphoma and is significantly heterogeneous among various subtypes. Despite of considerable advancements in treatment strategies for B-NHL, the prognosis of relapsed/refractory patients remains poor.
Main Text: It has been indicated that epigenetic dysregulation is critically associated with the pathogenesis of most hematological malignancies, resulting in the clinical targeting of epigenetic modifications.
Effect of POD24 on the prognosis of follicular and other indolent B-cell non-hodgkin lymphomas.
Ann Hematol
November 2024
Department of Hematology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Indolent B-cell non-Hodgkin lymphomas(B-NHL) encompass a heterogeneous category of lymphomas characterized by a wide range of pathological subtypes. With the application of chemoimmunotherapy with rituximab (R-chemo), the prognosis of patients has improved considerably, with a 10-year survival rate of 60-80%. Despite these advancements, a significant number of patients still experience disease progression during or shortly after initial treatment.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!